Publications by authors named "Utpal Kumar Sanki"

Article Synopsis
  • Alfuzosin is a new alpha-1a antagonist drug designed for treating lower urinary tract syndromes (LUTS) with minimal heart-related side effects.
  • A modified release (MR) formulation was created using a cost-effective method to enhance patient compliance by reducing the number of pills taken.
  • Clinical trials showed that this new formulation is safe and comparable in performance to the established reference drug, Uroxatral, under fasting conditions.
View Article and Find Full Text PDF

The comparative pharmacokinetic (PK) study of two brands of clindamycin hydrochloride (CAS 21462-39-5) was carried out on 32 healthy Indian subjects in an open label randomized, two way crossover, two period, two sequence, two treatment trial with a minimum washout period of 7 days. Plasma samples were collected at 10 min interval for the 1st hour, at 1 h interval for the next 6 h, at 2 h interval for next 12 h and finally at the 24th hour (pre-dose as baseline value) after drug administration. The concentrations of clindamycin in plasma were determined using high performance liquid chromatography (HPLC) technique with UV detector [lower limit of quantitation (LLOQ) 0.

View Article and Find Full Text PDF